IGFBP3 and neoplasm: To validate these findings in vivo, we established a mouse model of subcutaneous LUAD by injection of A549 cells with IGFBP3‐oe alone or FTO‐kd and IGFBP3‐oe in nude mice, and measured tumour volumes every 5 days (Figure 4E).